☆ 4.7 Article

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial

LANCET NEUROLOGY (2023)

Get Full Text
Add to Collection

Journal

LANCET NEUROLOGY
Volume 22, Issue 2, Pages 127-136

Publisher

Elsevier BV
DOI: 10.1016/s1474-4422(22)00495-1

Keywords

-

Categories

Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.